Parexel rolls out new eClinical tech to speed up study start-up

Parexel International ($PRXL) has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.

The company is launching a new version of ClinPhone, the randomization and trial supply management (RTSM) module of its banner MyTrials system. The latest version ships with pre-built tools for the patient, supply and site activities needed in the majority of trials, creating a plug-and-play system that lets investigators hit the ground running, according to Parexel.

The beginning of a study is often when researchers are required to keep the most plates spinning, simultaneously dealing with screening, enrollment, drug dispensation and supply distribution. That bottleneck can affect the outcome of a trial, and Parexel believes its eClinical technology can boost success rates by making study start-up faster and more efficient.

"Based upon our experience across thousands of studies, we have identified ways to standardize common functionality for patient screening, medication re-supply and other fundamental study activities," Parexel Informatics President Xavier Flinois said in a statement. "Our customers can simplify trial management activities, and ultimately start their trials more quickly, using our powerful and flexible RTSM technology."

Parexel's eClinical business, which dropped its former "Perceptive" moniker and took on the company name in February, has been its most reliable growth engine. The CRO's traditional drug development units have mostly ebbed and flowed with market trends, but its eClinical segment has long been a steady source of revenue growth. In the 9 months ended March 31, the business brought in $198.1 million, a 21.6% jump over the same period last year.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.